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aBstraCt
Imatinib is the most widely used drug in targeted therapy for chronic myelogenous leukaemia (CML). Few ophthal-
mic side effects like periorbital oedema, epiphora, ptosis, extraocular muscle palsy, blepharoconjunctivitis, glaucoma, 
papilledema, photosensitivity, retinal haemorrhage, and increased intraocular pressure are described with imatinib 
therapy. A 35-year-old male, a known case of CML with no ocular complaints, on treatment with imatinib for the 
preceding six weeks, presented with acute central serous chorioretinopathy in the left eye. Owing to his professional 
requirements for early visual recovery, he was treated with subthreshold micropulse laser with complete resolution of 
the subretinal fluid. This case report highlights acute central serous chorioretinopathy as a potential rare complication 
of imatinib therapy in CML patients, which requires regular and detailed ophthalmic evaluation so as to diagnose 
and treat it without any residual effects.
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introduCtion
Chronic myelogenous leukaemia (CML) is 
a clonal stem cell disorder of haemopoietic stem 
cells. It occurs due to reciprocal translocation be-
tween chromosomes 9 and 22, t (9; 22), which 
results in a fusion gene product BCR-ABL on chro-
mosome 22. Chronic myelogenous leukaemia ac-
counts for 15% of adult leukaemias with the me-
dian age of diagnosis being 67 years [1]. Imatinib 
mesylate (imatinib) specifically targets a set of pro-
tein tyrosine kinases and is the treatment of choice 
for patients with CML [2]. Chronic myelogenous 
leukaemia itself can lead to a varied spectrum of 
ocular presentations that includes retinal and iris 
neovascularisation, haemorrhages, glaucoma, vitre-
ous haemorrhages, Roth spots, nerve fibre infarcts, 
and papilledema [3, 4]. 
Imatinib treatment can also lead to certain oph-
thalmic side effects like periorbital oedema, epipho-
ra, ptosis, extraocular muscle palsy, blepharocon-
junctivitis, glaucoma, papilledema, photosensitiv-
ity, retinal haemorrhage, and increased intraocular 
pressure [5]. We report an unusual complication in 
the form of acute central serous chorioretinopathy 
in a patient of CML, who was started on imatinib 
therapy six weeks earlier, as well as its management. 
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To the best of our knowledge, it is first case of docu-
mentation of this vision-affecting complication in 
a patient of CML on imatinib therapy.
Case report
A 35-year-old Indian male, an active military 
soldier, a known case of CML on treatment, pre-
sented with diminution of vision in left eye for the 
preceding week. He was started on imatinib 400 mg 
(Tab) once daily as target therapy for CML about 
six weeks earlier, after BCR-ABL was detected as 
positive. The patient did not have any history of 
steroid use and it was not documented in his treat-
ment history. On evaluation he had best corrected 
visual acuity of 6/6 in his right eye and 6/36 in his 
left eye, with no ocular abnormality in the right 
eye. Left eye examination revealed normal anterior 
segment with large 6 DD size neurosensory detach-
ment in the posterior pole involving foveal cen-
tre with no evidence of any retinal haemorrhages 
or features of active vasculitis (Fig. 1A). Fundus 
fluorescein angiogram showed a single ink blot leak 
close to the foveal centre, with spectral domain opti-
cal coherence tomography (SD-OCT) confirming 
large neurosensory detachment involving the foveal 
centre (Fig. 1B and C).
Observation for spontaneous resolution is 
a standard treatment in patients of central serous 
chorioretinopathy. Owing to blast crisis, it was not 
possible to reduce the dosage of imatinib thera-
py, which was continued for the subsequent eight 
weeks. However, being an active military soldier, 
early visual recovery was required, so he was subject-
ed to subthreshold micropulse laser using a 532 nm 
green laser (Suprascan, Multispot Photocoagulator, 
Quantel medicals, Clermont-Ferrand, France) us-
ing 5% duty cycle with 250 mW power (titrated 
to 1/3 of power producing a just detectable burn 
outside the vascular arcades), duration 0.02 ms, 
and 36 confluent spots to focal leak. The patient 
was subsequently evaluated at 1 week, 4 weeks, and 
8 weeks post laser with BCVA, OCT, and Fundus 
autofluorescence, with substantial improvement in 
visual status and no adverse effects of laser treat-
ment. He had complete resolution of neurosensory 
detachment, which was confirmed on OCT with 
BCVA improving to 6/6 in LE without any side 
effects of subthreshold laser therapy at 8 weeks post 
treatment (Fig. 2A and B).
disCussion
Imatinib is the most common drug used for the 
targeted therapy of CML. In addition to inherent 
ophthalmic manifestation of CML, certain ophthal-
mic side effects like periorbital oedema, epiphora, 
ptosis, extraocular muscle palsy, blepharoconjuncti-
vitis, glaucoma, papilledema, photosensitivity, reti-
nal haemorrhage, and increased intraocular pressure 
are described with imatinib therapy [5]. Montero 
et al. also reported serous retinal detachment along 
with retinal haemorrhages in a 35-year-old woman 
but without angiographic evidence of any focal leak 
in a CML patient not on any therapy [6]. Nakashi-
ma et al. reported that imatinib induced interstitial 
Figure 1a. Colour fundus photograph of the left eye showing large (around 6 DD size) neurosensory detachment in posterior pole involv-
ing foveal centre. B. Fundus fluorescein angiogram of the same patient showing a single ink blot leak close to the foveal centre with some 
transmitted florescence. C. Spectral domain optical coherence tomography (SD-oCt) of the same patient confirming large neurosensory 
detachment involving the foveal centre
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lung disease after discontinuation of therapy in a pa-
tient who received treatment for 10 weeks [7].
Our patient developed diminution of vision in 
the left eye around six weeks after starting on imat-
inib therapy with FFA showing a single ink blot leak 
on the papillomacular bundle close to the foveal 
centre. He underwent subthreshold micropulse la-
ser treatment of the focal leak because early visual 
recovery was warranted owing to his professional 
requirement, with full recovery of vision and com-
plete resolution of neurosensory detachment over 
the subsequent eight weeks.
Imatinib usually does not cross the blood-ocular 
barrier; but can do so subsequent to damage to 
ocular or retinal microvasculature. It can lead to 
a vasculitis-like picture in which the effect on the 
retinal vasculature is seen early. Fluid retention is 
a common adverse effect and one of the impor-
tant dose-limiting toxicities mainly occurring in 
the periorbital area, and pleural and pericardial cav-
ity [8]. The most popular theory that can explain 
serous detachment is that imatinib inhibits the 
platelet-derived growth factor receptor (PDGFR), 
which regulates interstitial fluid homeostasis , and 
which probably also occurs in choroidal vasculature 
manifesting with central serous retinopathy [9].
Hence, it is a well-known fact that patients of 
CML are at high risk of loss of vision due to devel-
opment of glaucoma or retinal complications. The 
role of imatinib cannot be ruled out in causation of 
acute central serous retinopathy, especially in view 
of the important, documented side effect of fluid 
retention. It is imperative that CML patients on 
imatinib therapy should undergo regular detailed 
ophthalmic examinations so as to diagnose and treat 
potential vision-affecting complications, as demon-
strated in our present case.
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